There are 2934 resources available
2609 - Overall survival (OS) in KATE2, a phase 2 study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Presenter: Leisha Emens
Session: Proffered Paper - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
4204 - Assessment of Cardiotoxicity (CT) Associated with Doxorubicin (dox) in Patients (pts) with Advanced Soft Tissue Sarcoma (STS) in a Phase 3 Randomized Trial
Presenter: Robin Lewis Jones
Session: Proffered Paper – Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1872 - Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice
Presenter: Serena Di Cosimo
Session: Proffered Paper – Supportive and palliative care
Resources:
Abstract
Slides
Webcast
Introduction and 1st vote
Presenter: Christian Rolfo
Session: ctDNA vs. tissue biopsy
Resources:
Slides
Webcast
Liquid biopsy
Presenter: Dennis (Yuk-Ming) Lo
Session: ctDNA vs. tissue biopsy
Resources:
Slides
Webcast
Tissue biopsy
Presenter: Stefan Sleijfer
Session: ctDNA vs. tissue biopsy
Resources:
Slides
Webcast
2nd vote and conclusions
Presenter: Christian Rolfo
Session: ctDNA vs. tissue biopsy
Resources:
Slides
Webcast
Survivorship and delayed effects
Presenter: Anna Sophie Berghoff
Session: WHO grade II and III gliomas: State of the art management
Resources:
Slides
Webcast
YO “boxing” session - Take-home messages & discussion
Presenter: Javier Cortés
Session: YO “boxing” session
Resources:
Slides
Discussion led by Chair
Presenter: Amanda Psyrri
Session: Biomarkers for patient selection for checkpoint inhibitors in HNSCC: Where do we stand?
Resources:
Slides
Webcast